
Joseph Minhow Chan, MD, PhD
Medical Oncologist
Titles
Instructor
Clinical Expertise
Lung Cancer; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Small Cell Lung Cancer Transformation
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Chan accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 646-888-3486 Office Phone
- Speaks English and Spanish

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Columbia University; PhD, Columbia University
Residencies
Internal Medicine - Weill Cornell at New York Presbyterian
Fellowships
Medical Oncology - Memorial Sloan Kettering
Board Certifications
Internal Medicine; Medical Oncology
I am a board-certified medical oncologist specializing in the treatment of lung cancer and a physician-scientist specializing in computational biology and single-cell genomics, with a focus on small cell transformation in lung and prostate cancer.
Read more
As a clinician, I work in the inpatient setting, where I treat patients who have been admitted to Memorial Hospital. In the hospital, I work closely with a dedicated group of doctors, including world-renowned lung cancer experts, nurses and nurse practitioners, pharmacists, and support staff to deliver the highest-quality care possible. In addition to medical management, I strive to communicate with my patients and their families to ease the burden of uncertainty. Whether you are a patient or a family member, any experience with cancer can be scary. So much of the fear associated with cancer is fear of the unknown, and I will take the time to discuss the rationale and expectations for any diagnostic tests or treatments so that we can banish this fear as much as possible.
As a physician-scientist and computational biologist conducting cancer research at Sloan Kettering Institute (SKI), I aim to gain a better understanding of lineage plasticity, a poorly understood mechanism of therapeutic resistance and metastasis in cancer. A key example of plasticity in cancer is when adenocarcinoma escapes pressure from targeted therapies by transforming into a more aggressive disease called small cell cancer. This phenomenon arises in many different cancer types, including lung, prostate, bladder, uterine, cervical, gastrointestinal tract, and head and neck, among others. I also strive to use single-cell technologies to understand how lineage plasticity in lung and prostate cancer affects tumor progression, and how the surrounding microenvironment can impact this process. The overarching goal of this research is to identify a new class of drugs that can reverse plasticity, thereby restoring the disease’s original sensitivity to targeted therapies.
I completed my undergraduate studies in biomedical computation at Stanford University, my MD/PhD at Columbia University College of Physicians and Surgeons, my residency in internal medicine at Weill Cornell Medical Center at NewYork-Presbyterian, and, finally, my fellowship in oncology at Memorial Sloan Kettering Cancer Center. For my PhD work, I studied computational biology and developed new methods to model the topology of viral evolution and identify gene fusions in cancer. These methods supported the identification of a class of recurrent FGFR-TACC fusions in brain cancer; of note, this was the first time that this mutation was found in any cancer. Now, this mutation is an FDA-approved drug target in bladder and gallbladder cancer.
Awards and Honors
- Clinical Investigator Award, K08CA259161, National Cancer Institute (2021-Current)
- Young Investigator Award, American Society of Clinical Oncology & Conquer Cancer Foundation (2021-Current)
- Lung Cancer Research Fellowship, American Association for Cancer Research (2021)
- Harborside Endowed Merit Award, American Society of Clinical Oncology & Conquer Cancer Foundation (2021)
- World Conference on Lung Cancer Early Career Award, International Association for the Study of Lung Cancer (2021)
- Gerry Fellowship, Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2020-2021)
- Distinguished Young Investigator Award, EGFR Resisters (2020)
- T32 Investigational Cancer Therapeutics Training Program Grant, Memorial Sloan Kettering (2018-2020)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Chan’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Joseph Minhow Chan discloses the following relationships and financial interests:
-
Mirati Therapeutics
Ownership / Equity Interests
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].